Plain-English translation of NCT07424261 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Erythematosus, Systemic research guide →This is a real-world study following adults with systemic lupus erythematosus (SLE) who are prescribed anifrolumab as a new treatment. Researchers want to understand how well this medication works in everyday clinical practice—not in a controlled research setting—by tracking disease activity, symptoms, and quality of life over 24 months. The study will help doctors learn whether this treatment helps lupus patients reach important treatment goals like remission or low disease activity.
While this medication has been tested in clinical trials, doctors and patients need to know how it performs in real-world care, where patients often have other health conditions and take multiple medications. This study will provide that real-life evidence to guide treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would continue your normal medical care with your rheumatologist while taking the medication as prescribed. At routine appointments over 24 months, you would complete questionnaires about your lupus symptoms, disease activity, and quality of life. Your doctor would track standard lupus measures (like remission or low disease activity) and monitor for flares or any changes in organ involvement. There are no additional experimental procedures—the study simply observes and documents how you respond to treatment in your regular care.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Germany